Meridian Bioscience Profit Margin 2006-2018 | VIVO
Current and historical gross margin, operating margin and net profit margin for Meridian Bioscience (VIVO) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Meridian Bioscience net profit margin as of December 31, 2018 is 12.06%.
|Meridian Bioscience Annual Profit Margins
|Meridian Bioscience Quarterly Profit Margins
||Medical Products Manufacturing
Meridian Bioscience, Inc. is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and biopharmaceutical enabling technologies that help deliver answers. Its products provide accuracy, simplicity and speed for the early diagnosis and treatment of common medical conditions, such as C. difficile, H. pylori, foodborne diseases and respiratory infections. In addition, the company develops and manufactures a variety of biological and non-biological materials used in proficiency testing programs. Meridian diagnostic products are used outside of the human body and require little or no special equipment. Meridian Bioscience designs their products to enhance the well-being of the patient-while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal infections, serology, parasitology and fungal disease diagnosis.